Why A/B/C Recommendation Levels Matter in Pharmaceutical Procurement

In pharmaceutical procurement, purchasing decisions have traditionally been driven by historical sales data, pricing, supplier availability, and market demand. While these factors remain important, another increasingly valuable source of information is often overlooked: the recommendation levels in clinical practice guidelines.

Whether managing inventory for a hospital pharmacy, retail pharmacy chain, pharmaceutical wholesaler, or global drug distributor handling thousands of SKUs, procurement professionals face the same challenge:

• Which medicines should receive the highest purchasing priority?
• Which products require stable inventory levels?
• Which drugs should be stocked more cautiously?

As evidence-based medicine continues to shape clinical decision-making worldwide, clinical guidelines have become an important indicator of future prescribing behavior—and, ultimately, future market demand.

Understanding recommendation levels such as Class A, B, and C can help pharmaceutical procurement teams make smarter inventory decisions, optimize product portfolios, and improve supply chain efficiency.

What Are A/B/C Recommendation Levels?

Most national and international clinical guidelines classify treatment recommendations according to two key factors:

• The quality of clinical evidence
• The strength of the recommendation

Although different medical organizations use different grading systems, the overall principles are similar.

Class A Recommendation

Class A recommendations are supported by high-quality clinical evidence demonstrating clear therapeutic benefits. These treatments receive strong recommendations for routine clinical use.

Class B Recommendation

Class B recommendations are backed by substantial evidence, although the available data may be less comprehensive or less consistent than that supporting Class A therapies.

Class C Recommendation

Class C recommendations are generally based on limited clinical evidence, smaller studies, or expert consensus. Their use often depends on individual patient circumstances.

For clinicians, these recommendation levels guide treatment decisions. For procurement professionals, they provide valuable insight into how prescribing patterns—and therefore demand—may evolve over time.

Clinical guidelines are no longer simply medical references. They have become strategic tools for pharmaceutical purchasing and supply chain planning.

Why Recommendation Levels Influence Market Demand

Drug sales ultimately depend on physician prescribing behavior, and prescribing behavior is increasingly influenced by clinical guidelines.

Across therapeutic areas such as hypertension, diabetes, oncology, and autoimmune diseases, many healthcare systems now emphasize guideline adherence as part of quality-of-care initiatives. In some countries, reimbursement policies and hospital performance evaluations are also linked to compliance with evidence-based guidelines.

As a result, recommendation levels can directly influence:

• Physicians' prescribing preferences
• Long-term patient demand
• Reimbursement policies
• Medical education priorities
• Hospital formulary decisions

When a medicine is upgraded from Class B to Class A, demand often increases significantly. Conversely, if new evidence weakens a recommendation or superior alternatives emerge, market share may decline.

For procurement teams, updates to clinical guidelines frequently provide an earlier signal of future demand than sales reports alone.

Class A Medicines Should Be Procurement Priorities

For most healthcare organizations, medicines with Class A recommendations form the foundation of inventory planning.

These products typically offer:

• Strong clinical evidence
• Broad physician acceptance
• Widespread clinical use
• Stable market demand
• Long-term commercial potential

For example, in hypertension management, many angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), and fixed-dose combination therapies continue to receive strong guideline recommendations, supporting steady global demand.

Maintaining adequate inventory of these medicines helps reduce the risk of shortages that could disrupt patient care.

However, a Class A recommendation does not justify excessive stock levels. Procurement decisions should also consider regional disease prevalence, hospital specialties, and patient demographics to avoid unnecessary inventory costs.

Class B Medicines Offer Strategic Growth Opportunities

Compared with Class A therapies, Class B medicines are often found in rapidly evolving therapeutic areas.

Although supported by solid clinical evidence, these products may still be accumulating long-term safety and efficacy data.

From a business perspective, Class B medicines frequently represent some of the most attractive growth opportunities.

Procurement teams should closely monitor:

• Publication of major clinical trials
• Future guideline updates
• Changes in reimbursement policies
• Expansion of emerging therapeutic markets

Many innovative therapies begin with Class B recommendations before accumulating sufficient evidence to achieve Class A status.

Consequently, purchasing decisions should not rely solely on current sales performance. Combining clinical guideline monitoring with market intelligence allows distributors to identify future growth opportunities earlier.

For pharmaceutical wholesalers and distributors, these medicines can become important drivers of long-term business expansion.

Class C Medicines Still Require Strategic Inventory Management

A common misconception is that Class C recommendations indicate unimportant medicines.

In reality, Class C simply reflects limited evidence—not necessarily limited clinical value.

Many Class C medicines may:

• Serve highly specialized patient populations
• Treat rare diseases
• Represent innovative therapeutic approaches
• Lack large-scale clinical trials
• Be indicated for niche clinical situations

Rather than eliminating these products from inventory, organizations should adopt a flexible stocking strategy based on historical utilization, departmental demand, and anticipated market needs.

This approach is particularly important for high-cost, low-volume specialty medicines, where both stock shortages and excess inventory can be financially significant.

Combining Clinical Guidelines with Market Intelligence

Clinical recommendation levels should never be the only factor influencing procurement decisions.

Leading pharmaceutical supply chain organizations increasingly combine clinical evidence with commercial data to build more accurate inventory strategies.

A comprehensive evaluation framework may include:

• Clinical guideline recommendation levels
• Reimbursement status
• Historical sales performance
• Hospital formulary inclusion
• Regional patient demand
• Competitive market dynamics

Integrating these factors enables procurement teams to identify:

• Medicines requiring expanded inventory
• Products that need stable supply
• Drugs that require tighter inventory control

This data-driven approach improves supply reliability while making more efficient use of working capital.

For pharmaceutical distributors, dynamic inventory planning based on evolving clinical evidence is becoming an increasingly important competitive advantage.

Companies such as DengYue Medicine, which connect pharmaceutical manufacturers with healthcare providers worldwide, are expanding their focus beyond sales data alone. By monitoring changes in clinical guidelines alongside therapeutic trends, they can better anticipate demand, optimize inventory allocation, and strengthen supply chain responsiveness.

What This Means for Pharmaceutical Distributors

As evidence-based medicine continues to evolve, pharmaceutical supply chain management is shifting from experience-based decision-making toward data-driven strategies.

Relying solely on historical sales data will become increasingly insufficient.

For pharmaceutical distributors, updates to clinical guidelines are more than medical news—they provide early insight into future market demand.

Organizations that continuously monitor recommendation level changes, emerging therapeutic trends, and regional demand patterns are better positioned to:

• Forecast demand more accurately
• Optimize product portfolios
• Improve inventory turnover
• Reduce supply chain risks
• Respond more quickly to changing market conditions

This proactive approach enables distributors to create greater value for both manufacturers and healthcare providers.

Conclusion

Clinical guideline recommendation levels primarily reflect clinical value, but clinical value ultimately shapes market demand.

Class A recommendations identify medicines that deserve procurement priority. Class B recommendations often highlight future growth opportunities, while Class C recommendations require more targeted inventory management.

For procurement professionals, effective inventory planning should combine clinical guideline insights with market intelligence, patient demand, and commercial considerations.

As the pharmaceutical industry continues to evolve, distributors are moving beyond their traditional logistics role to become strategic supply chain partners. By integrating clinical evidence, market analytics, and demand forecasting, companies such as DengYue Pharma can help manufacturers and healthcare institutions build more resilient, efficient, and responsive pharmaceutical supply chains—creating a lasting competitive advantage in an increasingly data-driven healthcare market.